These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38369639)

  • 21. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
    Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
    Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The US Food and drug administration: drug information resource for formulary recommendations.
    Marchand HC; Ros BJ; Fine AM; Kremzner ME
    J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generating comparative evidence on new drugs and devices after approval.
    Cipriani A; Ioannidis JPA; Rothwell PM; Glasziou P; Li T; Hernandez AF; Tomlinson A; Simes J; Naci H
    Lancet; 2020 Mar; 395(10228):998-1010. PubMed ID: 32199487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union.
    de Jong AJ; Santa-Ana-Tellez Y; van Thiel GJMW; Zuidgeest MGP; Siiskonen SJ; Mistry D; de Boer A; Gardarsdottir H;
    Clin Pharmacol Ther; 2021 Jun; 109(6):1517-1527. PubMed ID: 33666223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory pathways for vaccines for developing countries.
    Milstien J; Belgharbi L
    Bull World Health Organ; 2004 Feb; 82(2):128-33. PubMed ID: 15042235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact Assessment of Divergence on Post-approval Changes Classifications of Latin America Region With Europe and the United States, and Propositions to Harmonize Classification Based on Risk as a Path to Build the Trust Between National Regulatory Agencies.
    De Lucia ML; Comesaña C; Rodriguez H; Dangy-Caye A
    Clin Ther; 2024 Feb; 46(2):164-172. PubMed ID: 38092583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug shortages in Israel: regulatory perspectives, challenges and solutions.
    Schwartzberg E; Ainbinder D; Vishkauzan A; Gamzu R
    Isr J Health Policy Res; 2017; 6():17. PubMed ID: 28392910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.
    Regnstrom J; Koenig F; Aronsson B; Reimer T; Svendsen K; Tsigkos S; Flamion B; Eichler HG; Vamvakas S
    Eur J Clin Pharmacol; 2010 Jan; 66(1):39-48. PubMed ID: 19936724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 35. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union.
    Hoekman J; Boon W
    Soc Sci Med; 2019 Feb; 222():76-83. PubMed ID: 30605802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six Sigma: not for the faint of heart.
    Benedetto AR
    Radiol Manage; 2003; 25(2):40-53. PubMed ID: 12800564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effectiveness of web-based programs on the reduction of childhood obesity in school-aged children: A systematic review.
    Antwi F; Fazylova N; Garcon MC; Lopez L; Rubiano R; Slyer JT
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-14. PubMed ID: 27820152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.